BioCentury
ARTICLE | Clinical News

CPP-115: Phase I started

September 8, 2014 7:00 AM UTC

Catalyst began a 2-part, U.S. Phase Ib trial to evaluate single and multiple doses of CPP-115 in up to 38 healthy, male volunteers. The trial will evaluate increases in brain GABA levels, which Catalyst believes is a biomarker for efficacy of CPP-115.

The first, open-label part will evaluate single descending doses in up to 3 cohorts of 2 healthy volunteers each. The second, double-blind part will evaluate multiple ascending doses in 4 cohorts of 8 healthy volunteers each. ...